Our History

2022
2022

2022

Agenus presents data on botensilimab (next-gen CTLA-4)/balstilimab (PD-1) combination in heavily pretreated metastatic microsatellite stable colorectal cancer 

Combination results in 24% response rate and 73% disease control rate 


AGEN1571 (anti-ILT2) enters clinical development

Preclinical data support best-in-class potential for Agenus' first wholly-owned clinical stage myeloid targeting agent

2021
2021

2021

Agenus and BMS enter licensing agreement for AGEN1777 (TIGIT bispecific)

AGEN1777 enters clinical development


Agenus presents data on botensilimab (next-gen CTLA-4) in solid tumors

Botensilimab demonstrates clinical responses across nine cold and treatment-resistant cancer types


Agenus publishes data on balstilimab (PD-1)/zalifrelimab (CTLA-4) combination in 2L cervical cancer

Combination resulted in ~2x response rate (33%) vs. what has been reported for pembrolizumab in PD-L1+ patients


Agenus subsidiary MiNK Therapeutics announces IPO and becomes publicly traded on Nasdaq under the symbol INKT

MiNK is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases


Agenus subsidiary SaponiQx launches to drive innovation in adjuvant manufacturing, novel adjuvant discovery, and vaccine design

2020
2020

2020

Agenus and Betta enter licensing agreement for balstilimab (PD-1) and zalifrelimab (CTLA-4) in greater China

2019
2019

2019

Botensilimab (next-gen CTLA-4), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ) enter clinical development


Agenus and UroGen enter zalifrelimab collaboration for intravesical treatment of urinary tract cancers

2018
2018

2018

MK-4830 (ILT4), INCAGN2385 (LAG-3) and INCAGN02390 (TIM-3) enter clinical development


Agenus and Gilead enter collaboration to develop next-generation immuno-oncology therapies

2017
2017

2017

Balstilimab (PD-1) enters clinical development


FDA approves GSK’s Shingrix® containing QS-21 Stimulon™

2016
2016

2016

Zalifrelimab (CTLA-4); INCAGN1949 (GITR) and INCAGN2385 (OX40) enter clinical development

2015
2015

2015

Agenus and Incyte enter global I-O discovery alliance


Agenus acquires XOMA manufacturing plant and talent

2014
2014

2014

Agenus acquires 4-AB with multiple checkpoint antibody programs


Agenus and Merck enter antibody discovery collaboration

2000
2000

2000

Agenus completes IPO and becomes publicly traded on Nasdaq under the symbol AGEN


Agenus acquires Aquila Biopharmaceuticals and QS-21 Stimulon™

Potent immune adjuvant in GSK’s Shingrix® and Mosquirix™

1999+
1999+

1999+

Prophage reveals robust clinical responses in melanoma, renal cell carcinoma, colorectal cancer, and other indications

1994
1994

1994

Agenus (previously Antigenics) founded to develop first individualized neoantigen vaccine, Prophage